Hakutulokset - Lheureux, Stephanie

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer Tekijä Colombo, Ilaria, Lheureux, Stephanie, Oza, Amit Manulal

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations Tekijä Madariaga, Ainhoa, Lheureux, Stephanie, Oza, Amit M.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers Tekijä Kasherman, Lawrence, Liu, Shiru (Lucy), Karakasis, Katherine, Lheureux, Stephanie

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events Tekijä Madariaga, Ainhoa, Bowering, Valerie, Ahrari, Soha, Oza, Amit M, Lheureux, Stephanie

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention Tekijä Karakasis, Katherine, Burnier, Julia V., Bowering, Valerie, Oza, Amit M., Lheureux, Stephanie

Hae kokoteksti Hae kokoteksti Hae kokoteksti

The motivations and methodology for high-throughput PET imaging of small animals in cancer research Tekijä Aide, Nicolas, Visser, Eric P., Lheureux, Stéphanie, Heutte, Natacha, Szanda, Istvan, Hicks, Rodney J.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature Tekijä Aide, Nicolas, Hicks, Rodney J., Le Tourneau, Christophe, Lheureux, Stéphanie, Fanti, Stefano, Lopci, Egesta

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature Tekijä Kasherman, Lawrence, Doi, Jeffrey, Karakasis, Katherine, Schiff, Jeffrey, Kitchlu, Abhijat, Lheureux, Stephanie, Oza, Amit M.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria Tekijä Wintersperger, Bernd J, Calvillo-Argüelles, Oscar, Lheureux, Stephanie, Houbois, Christian P, Spreafico, Anna, Bedard, Philippe L, Neilan, Tomas G, Thavendiranathan, Paaladinesh

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient Tekijä Colombo, Ilaria, Garg, Swati, Danesh, Arnavaz, Bruce, Jeffrey, Shaw, Patricia, Tan, Qian, Quevedo, Rene, Braunstein, Marsela, Oza, Amit M., Pugh, Trevor, Lheureux, Stephanie

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series Tekijä Kasherman, Lawrence, Garg, Swati, Tchrakian, Nairi, Clarke, Blaise, Karakasis, Katherine, Kim, Raymond H., Stockley, Tracy L., Dhani, Neesha, Oza, Amit M., Lheureux, Stephanie

Hae kokoteksti Hae kokoteksti Hae kokoteksti

MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer Tekijä Madariaga, Ainhoa, Lau, Jenny, Ghoshal, Arunangshu, Dzierżanowski, Tomasz, Larkin, Philip, Sobocki, Jacek, Dickman, Andrew, Furness, Kate, Fazelzad, Rouhi, Crawford, Gregory B, Lheureux, Stephanie

Hae kokoteksti Hae kokoteksti Hae kokoteksti

(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Re... Tekijä Lheureux, Stéphanie, Lecerf, Charlotte, Briand, Mélanie, Louis, Marie-Hélène, Dutoit, Soizic, Jebahi, Abdelghani, Giffard, Florence, Fournier, Cécile Blanc, Batalla, Alain, Poulain, Laurent, Aide, Nicolas

Hae kokoteksti Hae kokoteksti

ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI) Tekijä Banerjee, Susana, Stewart, James, Porta, Nuria, Toms, Christy, Leary, Alexandra, Lheureux, Stephanie, Khalique, Saira, Tai, Jeremy, Attygalle, Ayoma, Vroobel, Katherine, Lord, Christopher J, Natrajan, Rachael, Bliss, Judith

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry Tekijä Music, Milena, Iafolla, Marco, Soosaipillai, Antoninus, Batruch, Ihor, Prassas, Ioannis, Pintilie, Melania, Hansen, Aaron R., Bedard, Philippe L., Lheureux, Stephanie, Spreafico, Anna, Razak, Albiruni Abdul, Siu, Lillian L., Diamandis, Eleftherios P.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis Tekijä Iafolla, Marco A J, Yang, Cindy, Chandran, Vinod, Pintilie, Melania, Li, Quan, Bedard, Philippe L, Hansen, Aaron, Lheureux, Stephanie, Spreafico, Anna, Razak, Albiruni A, Hakgor, Sevan, Giesler, Amanda, Pugh, Trevor J, Siu, Lillian L

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening Tekijä Gu, Shengqing, Lheureux, Stephanie, Sayad, Azin, Cybulska, Paulina, Hogen, Liat, Vyarvelska, Iryna, Tu, Dongsheng, Parulekar, Wendy R., Nankivell, Matthew, Kehoe, Sean, Chi, Dennis S., Levine, Douglas A., Bernardini, Marcus Q., Rosen, Barry, Oza, Amit, Brown, Myles, Neel, Benjamin G.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy Tekijä Vigneron, Nicolas, Meryet-Figuière, Matthieu, Guttin, Audrey, Issartel, Jean-Paul, Lambert, Bernard, Briand, Mélanie, Louis, Marie-Hélène, Vernon, Mégane, Lebailly, Pierre, Lecluse, Yannick, Joly, Florence, Krieger, Sophie, Lheureux, Stéphanie, Clarisse, Bénédicte, Leconte, Alexandra, Gauduchon, Pascal, Poulain, Laurent, Denoyelle, Christophe

Hae kokoteksti Hae kokoteksti Hae kokoteksti

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Tekijä Tew, William P., Lacchetti, Christina, Ellis, Annie, Maxian, Kathleen, Banerjee, Susana, Bookman, Michael, Brown Jones, Monica, Lee, Jung-Min, Lheureux, Stéphanie, Liu, Joyce F., Moore, Kathleen N., Muller, Carolyn, Rodriguez, Patricia, Walsh, Christine, Westin, Shannon N., Kohn, Elise C.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors Tekijä Yang, S. Y. Cindy, Lheureux, Stephanie, Karakasis, Katherine, Burnier, Julia V., Bruce, Jeffery P., Clouthier, Derek L., Danesh, Arnavaz, Quevedo, Rene, Dowar, Mark, Hanna, Youstina, Li, Tiantian, Lu, Lin, Xu, Wei, Clarke, Blaise A., Ohashi, Pamela S., Shaw, Patricia A., Pugh, Trevor J., Oza, Amit M.

Hae kokoteksti Hae kokoteksti Hae kokoteksti